Client programs using CHOMax follow platform-defined workflows and phase-appropriate practices across the development lifecycle.
The MarketWatch News Department was not involved in the creation of this content. SAN DIEGO, Sept. 15, 2025 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO for complex biologics and ...
10d
Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf," cell therapies for serious medical conditions, ...
In a new study published in Nature Communications titled, “The reference genome of the human diploid cell line RPE-1,” researchers from University of Rome La Sapienza have produced the first reference ...
Lineage Cell Therapeutics (LCTX) announced the receipt of an induced pluripotent stem cell line containing hypoimmunity edits, from Factor ...
New offering provides drug developers with flexible and powerful cell line development options for monoclonal antibodies, multi-specific and complex molecules SEATTLE--(BUSINESS WIRE)-- As drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback